Ask Vendit Off-Topic Questions Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Ask Vendit Off-Topic Questions

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Vendit™ who wrote (2456)	12/7/2004 7:53:46 AM
From: Walkingshadow	Read Replies (1) of 8752

Re ALXN... this on the wires. There's tons of good biotech news out today. The sector should do well: ALXN Alexion Pharm reports results of 2 yr study Company announced that data showed that eculizumab administration for two years was associated with statistically significant reductions in hemolysis and in the need for blood transfusions, a key clinical objective of the trial. This observation will be further tested as more patients are treated in the ongoing Phase III program.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next